Background: The chemokine CCL5 is involved in the recruitment of immune cells and a subsequent activation of hepatic stellate cells (HSC) after liver injury. We here investigate whether inhibition of CCL5 oligomerization and glycosaminoglycan binding by a mutated CCL5 protein ( 44 AANA 47 -CCL5) has the potential to ameliorate liver cell injury and fibrosis in vivo.
Introduction
Acute and chronic liver diseases are a major cause of morbidity and mortality worldwide. In most diseases an inflammatory response within the liver is a mainstay of tissue damage [1] . After acute injury, an overwhelming immune response can lead to massive hepatocyte damage and subsequent liver failure [2] . On the other hand a continuous, low-level inflammation is a central pathophysiological aspect of liver fibrogenesis which ultimately leads to the development of liver cirrhosis in a significant number of cases [3] . Therefore, elucidation of pivotal inflammatory pathways in liver disease models might of great clinical interest as interference with these pathways bears the potential for new therapeutic options in diverse acute and chronic liver diseases.
The inflammatory infiltrate within the damaged liver consists of different immune cells subsets, including macrophages, dendritic cells, T cells, NK cells, NKT-cells and B-cells. Most of these cells are recruited into the liver along a chemotactic gradient. Classical chemoattractant molecules are chemokines, which are long known to govern the directed migration of leukocytes to sites of inflammation. In recent years, an important role of chemokines has also been deciphered in liver diseases [4] . Chemokines bind with high affinity to classical G-protein coupled receptors on the cell membrane of target cells and with lower affinity to glycosaminoglycans (GAG) of the extracellular matrix and endothelial cell surfaces [5] . Interaction of chemokines with GAG appears to be essential for the in vivo activity of certain chemokines and is considered as a prerequisite for establishing a chemotactic gradient across endothelial barriers [6] . Another biochemical characteristic of chemokines is their ability to form higher order oligomers what appears to be essential for their GAG binding and chemotactic activity in vivo [7] .
CCL5 (traditional name: regulated upon activation, normally T cell expressed and secreted, RANTES) belongs to the CC family of inflammatory chemokines and is expressed by many liver resident and infiltrating cells [8] . In humans, CCL5 expression is upregulated in acute and chronic liver damage [9, 10, 11] and functional Ccl5 gene variants have been associated with inflammatory liver damage [12, 13] and treatment response [14] . Notably, in murine models of experimental fibrosis, CCL5 and its receptors CCR1 and CCR5 have been shown to be essential for fibrosis progression [9, 15] . Furthermore, antagonism of the CCL5 receptors with Met-CCL5 ameliorated liver fibrosis and accelerated the regression of scar formation in vivo [9] . Thus, this particular chemokine might be an attractive candidate for anti-inflammatory or anti-fibrotic therapies of liver diseases. However, chemokine receptor antagonism bears the potential for numerous unwanted side effects [16] . Therefore, other therapeutic strategies of chemokine antagonism should be systematically investigated.
Based on this background, we here investigate a novel therapeutic approach to interfere with the chemokine CCL5 in experimental liver damage models. We show that administration of the CCL5 mutant 44 [AANA]
47
-CCL5, which loses the ability to oligomerise, but forms inactive heterodimers with wild-type CCL5 and loses 80% of its capacity to bind to GAG [17] , strongly reduces acute liver injury and tissue fibrosis in vivo.
Materials and Methods

Murine in vivo experiments
Male wild-type (WT) mice on the C57BL/6 background (purchased from Charles River Laboratories) were subjected at the age of 8 weeks to two different liver damage models. In the first model, WT mice received a single intraperitoneal (i.p.) injection of carbon tetrachloride (CCl 4 n = 12/group) were administered i.p. concomitantly to CCl 4 . In all mice, serum samples were obtained via cardiac puncture and livers were harvested for histological and biochemical analysis.
All animals were housed under specific-pathogen-free conditions in the animal facility of the RWTH University hospital Aachen. The experiments were carried out after approval by the animal welfare board at the Bezirksregierung Cologne, Germany (permit number 50.203.2-AC 5a, 51/06).
Histological and biochemical evaluation of liver damage
Liver fibrosis was assessed histologically by quantification of the Sirius-red positive area on 10 low power (406) fields/slide by use of the NIH software Image J, which is available from http://rsbweb. nih.gov/. Hepatic collagen content was analyzed biochemically by photometric measurement of the collagen specific amino acid hydroxyproline as recently described [9] . The intrahepatic expression of a-smooth muscle antigen (a-SMA) was assessed histologically with a mouse anti-SMA (Clone1A4, Dako) antibody. Immunohistochemical stainings for immune cell infiltration were performed in cooperation with the Institute of Pathology of University Hospital Bonn, Germany. The following antibodies were used: CD45, rat Clone30-F11 (BD Sciences); CD3, rabbit Clone SP7 (LabVision); F4/80, rat Clone BM8 (Dianova).
Hepatic immune cell isolation and flow cytometry analysis
Single-cell suspensions were isolated from freshly harvested livers using mechanical and enzymatic digestion. Viable white blood cells were purified from the suspension by centrifugation for 20 min at 8006 g with a density gradient separation medium (Lymphocyte, PAA Laboratories). PBMCs were collected from the gradient/supernatant interface and then washed in Hank's balanced salt solution (PAA Laboratories) supplemented with 1% bovine serum albumin and 2 mM ethylene diamine tetraacetic acid (EDTA). For flow cytometry analysis, cells were stained with fluorochrome-conjugated antibodies for CD3, CD4, CD8, CD45 and NK1.1 (all antibodies from Bioscience) and the relative numbers were quantified using the FACSCanto II (Becton Dickinson). Data were analyzed using FlowJo software (Tree Star).
a-SMA Western blot
Snap-frozen liver samples were homogenised in 1 ml RIPA buffer (20 mM Tris-HCl, 150 mM NaCl, 2% Nonidet P40, 0.1% SDS, 0.5% Na-deoxycholate) with proteinase inhibitor (Mini Complete Protease Inhibitor Cocktail Tablets, Roche Applied Science) for isolation of total protein. Western blotting of a-SMA was performed from total liver protein, using a monoclonal mouse anti-mouse a-SMA antibody (Millipore). The primary antibody was visualized using horseradish peroxidase-conjugated antimouse IgG (DAKO) and the PIERCE ECL Western Blotting Substrate (Thermo Scientific). b-actin was used as loading control.
mRNA expression analysis of murine fibrogenic and inflammatory genes
Total RNA was isolated from livers with peqGold TriFast (Peqlab) and reversely transcribed using RevertAid Premium FS 47 ]-CCL5 treated WT mice (see above) were isolated using standard protocols. Cells were cultured for 24 hours in RPMI-1640 medium (PAA Laboratories) and transferred to another tissue culture flask. The cell concentration was adjusted to 8610 5 cells per ml. For conditioned media, splenocyte suspensions were incubated for 48 hours with 10 mg/ml Concanavalin A (SigmaAldrich). The supernatant was centrifuged for 10 min at 9006g to remove cells and debris.
Cell migration assay
A cell migration assay was performed using a modified Boyden Chamber. The stellate cell line GRX [18] 47 ]-CCL5 treated WT mice in the lower chamber. After 4 hours of incubation at 37uC, cells that migrated to the lower chamber were counted in 6 randomly chosen (magnification, 6100) fields. All experiments were replicated at least twice in quadruplicates.
Cell proliferation assay
GRX cells were starved for 16 hours in RPMI-1640 medium without FCS and stimulated for 24 hours with conditioned media from splenocytes of treated and untreated WT mice (see above). As controls RPMI-1640 medium with 10% FCS respectively without FCS was used. Proliferation of cells was measured by colorimetric immunoassay (Cell Proliferation Elisa, Roche Applied Science) following the manufacturer's instructions.
Statistical analysis
Data are given as means 6 SEM. Continuous variables were compared by two-sided t-tests with Welch's correction in case of unequal variances. P-values less than 0.05 were considered significant in all analyses. Statistical tests were performed by GraphPad Prism 5. 4 which is not modifiable by immune interventions. Furthermore, it should be noted that the ALT levels 48 h after CCl 4 administration are still much higher that the ALT levels in naïve animals. The same results were obtained for AST levels (data not shown). Decreased hepatocellular damage at 48 h was also reflected by a lower extend of hepatic necrosis as assessed by histology (Fig. 1B) . Since Fig. 2B ) and a reduced hepatic concentration of the collagen-specific amino acid hydroxyproline (reduction of 30.1%, P,0.01, Fig. 2C ), respectively. Although there was also a trend towards lower ALT levels, Furthermore, the mRNA expression of the fibrosis-associated genes Col1a1 and Timp1 was significantly reduced in the livers of [ 44 AANA 47 ]-CCL5 compared to vehicle treated mice (both P,0.05, Fig. 3A ). In addition, the mRNA expression of the important fibrogenic cytokine Tgf-b was reduced by 32% in [   44   AANA 47 ]-CCL5 treated mice compared to vehicle treated mice, although this difference did not reach statistical significane due to the high variation of expression within the groups. Since Timp1 is mainly expressed by hepatic stellate cells, we also assessed the activation status of these pivotal pro-fibrogenic cells [20] by determination of aSMA expression. As shown in figure 3B (Fig. 4, upper panel) . Since chemokines, including CCL5, are mainly secreted by T-cells and monocytes/macrophages during liver fibrogenesis [21] , we specifically determined the recruitment of these cells into the liver at peak of fibrosis. As depicted in figure 4 , the infiltration of both cell populations was indeed reduced in [   44   AANA 47 ]-CCL5 treated mice as assessed by immunohistochemistry for CD3 and F4/80, respectively. As CCL5 is a main chemoattractant for both of these cell populations [22] 47 ]-CCL5 treated mice significantly reduced the migration (Fig. 5A ) and the proliferation (Fig. 5B ) of hepatic stellate cells in vitro. As both aspects are important parameters of these cells during fibrogenesis [20] , [ 44 AANA 47 ]-CCL5 appears to also impact the biology of these cells by modulating qualitative changes of the immune response outside the liver.
Results
Discussion
The findings presented in the current study further establish an important role of the CC chemokine CCL5 in acute and chronic liver diseases. There is now ample evidence that this particular chemokine and its receptors play a functional role in murine models of acute [23] and chronic liver diseases [9, 15] . Furthermore, expression data and genetic analysis also suggest that CCL5 is involved in the pathogenesis of liver diseases in humans [12, 13, 14, 24] . Thus, CCL5 might be an attractive candidate for antagonistic studies to inhibit the progression and/or accelerate the regression of chronic liver diseases. Indeed, we could recently show that administration of an amino-terminally modified CCL5 molecule (Met-CCL5 [25] ), which is an antagonist of the CCL5 receptors CCR1 and CCR5, is able to ameliorate experimental liver damage in mice [9] . However, this particular antagonist blocks not only the action of CCL5 but also of other ligands of these chemokine receptors, including CCL3 and CCL4, which might have differential effects within and outside the liver [16] . We therefore investigated another principle of interference with the chemokine system in the current study which is not based on receptor antagonism, and might exhibit another pattern of side effects. The mutated chemokine [   44   AANA 47 ]-CCL5 is known to interfere with heparin binding and oligomerization of CCL5, which are both important biological aspects of it's activity in vivo [26, 27] . This antagonist has been shown to limit inflammatory cell recruitment into the peritoneal cavity, bronchoalveolar air space and the CNS in mice, thereby ameliorating the phenotype of inflammation in these organs [17] . Furthermore, [ 44 AANA 47 ]-CCL5 is able to ameliorate myocardial reperfusion injury in atherosclerotic mice [19] . We here extend these earlier findings by showing that systemic administration of [ 44 AANA 47 ]-CCL5 is also able to strongly inhibit the infiltration of immune cells into the damaged liver. This therapeutical effect was true for an acute model of liver injury as well as a chronic model leading to liver fibrosis. As it is now well established that infiltrating immune cells play a pivotal role in both phenotypes of liver disease [28] , these effects of [ 44 AANA 47 ]-CCL5 might be considered as the driving force behind the observed reduction of liver damage. Since T-cells and macrophages are known to carry receptors for CCL5 [29] , we systematically addressed the infiltration of these cells into the liver by immunocytochemistry. As depicted in figure 4 , the infiltration of both of these cell populations was indeed reduced in [   44   AANA 47 ]-CCL5 compared to vehicle treated mice. As T-cells [30] and monocytes/macrophages [31] are considered as pivotal pro-fibrogenic cell populations, these results might largely explain the phenotype observed in our models. sequester endogenous CCL5 by forming non-functional heterodimers [17] needs to be analyzed in further studies. Furthermore, other cytokines might be involved in the modulation of stellate cell behaviour. In a first attempt to identify these cytokines, we determined a subset of these molecules in the conditioned media of activated splenocytes, but could not detect major differences between cells isolated [ 44 AANA 47 ]-CCL5 and vehicle treated mice (data not shown). Thus, the identification of the molecules involved in the modulation of HSC behaviour in our models is still warranted but beyond the scope of the current study.
In summary, the current results suggest that interference with oligomerization and glycosaminoglycan binding of the chemokine CCL5 is able to ameliorate experimental liver injury and fibrosis in vivo. Although we cannot decide from our data that this approach is associated with fewer side effects than direct chemokine receptor antagonism, this strategy of immune intervention might be further evaluated as a novel option for the treatment of liver diseases.
